Edition:
United Kingdom

Kamada Ltd (KMDA.OQ)

KMDA.OQ on NASDAQ Stock Exchange Global Select Market

5.91USD
15 Oct 2018
Change (% chg)

$-0.00 (-0.08%)
Prev Close
$5.91
Open
$5.94
Day's High
$5.94
Day's Low
$5.91
Volume
493
Avg. Vol
5,777
52-wk High
$6.43
52-wk Low
$4.30

Latest Key Developments (Source: Significant Developments)

Kamada Announces Collaboration With Hospitals To Evaluate Its Product For Preemption Of Type Of Graft-Versus-Host Disease
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Kamada Ltd ::KAMADA ANNOUNCES COLLABORATION WITH A CONSORTIUM OF PROMINENT HOSPITALS LED BY THE MOUNT SINAI HOSPITAL TO EVALUATE ITS ALPHA-1 ANTITRYPSIN PRODUCT FOR PREEMPTION OF STEROID REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE.KAMADA SAYS ANNOUNCED COLLABORATION WITH MOUNT SINAI ACUTE GVHD INTERNATIONAL CONSORTIUM.KAMADA LTD - RECEIVED EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE ALPHA-1 ANTITRYPSIN FOR PREEMPTION OF GVHD USING MAGIC BIOMARKERS.KAMADA SAYS STUDY OF ALPHA-1-ANTITRYPSIN WILL BE INITIATED IN Q1 OF 2018.KAMADA LTD - TOP-LINE RESULTS FROM ALPHA-1-ANTITRYPSIN STUDY ARE EXPECTED TO BE AVAILABLE IN SECOND HALF OF 2019.  Full Article

Kamada announces new supply agreement with international organization for KamRAB
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Kamada Ltd :Kamada announces new supply agreement with international organization for KamRAB for post-exposure prophylaxis against rabies infection.Kamada Ltd - the ‍three-year supply agreement will extend through 2020, and is expected to generate revenues for Kamada of approximately $13 million​.  Full Article

Kamada and ‍Chiesi Farmaceutici terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Kamada Ltd ::Kamada Ltd - Co, ‍chiesi Farmaceutici S.P.A. mutually agree to terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy.Kamada Ltd - ‍Kamada now maintains full, worldwide commercial rights to its inhaled aat​.Kamada - ‍ no financial implications related to termination of agreement for inhaled alpha-1 antitrypsin therapy.  Full Article

BRIEF-Kamada Ltd Says Kedrab Has Been Launched In U.S.

* KAMADA LTD - KEDRAB HAS BEEN LAUNCHED IN U.S. Source text for Eikon: Further company coverage:

No consensus analysis data available.